Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
02 Oct 2024
Historique:
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 2 10 2024
Statut: aheadofprint

Résumé

Cancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort. In this multicenter phase I trial, we enrolled participants with HIV-associated KS on antiretroviral therapy with CD4 Thirty-two cisgender men enrolled with baseline median CD4 Pembrolizumab yielded a high rate of durable responses in HIV-associated KS. imAEs were successfully managed with standard guidelines.

Identifiants

DOI: 10.1200/JCO.24.00640 PMID: 39356983
pubmed: 39356983
doi: 10.1200/JCO.24.00640
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

JCO2400640

Auteurs

Kathryn Lurain (K)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
ORCID: 0000-0002-5794-7292

Ramya Ramaswami (R)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
ORCID: 0000-0001-5709-4675

Irene Ekwede (I)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Vanessa Eulo (V)

University of Alabama at Birmingham, Birmingham, AL.
ORCID: 0000-0003-2304-2222

Gaurav Goyal (G)

University of Alabama at Birmingham, Birmingham, AL.
ORCID: 0000-0001-6148-5177

Manoj Menon (M)

Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
ORCID: 0000-0002-4981-0376

Thomas A Odeny (TA)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
ORCID: 0000-0002-1644-2378

Elad Sharon (E)

Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Dana-Farber Cancer Institute, Boston, MA.
ORCID: 0000-0002-0044-9719

Michael J Wagner (MJ)

Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
Dana-Farber Cancer Institute, Boston, MA.
ORCID: 0000-0002-0753-9282

Chia-Ching Jackie Wang (CJ)

University of California San Francisco, San Francisco, CA.

Nina Bhardwaj (N)

Icahn School of Medicine at Mount Sinai Hospital, New York, NY.

Philip A Friedlander (PA)

Icahn School of Medicine at Mount Sinai Hospital, New York, NY.

Maher Abdul-Hay (M)

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY.
ORCID: 0000-0003-1041-7689

Elena M Cornejo Castro (EM)

Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.
ORCID: 0000-0003-1480-1397

Nazzarena Labo (N)

Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.

Vickie Ann Marshall (VA)

Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.

Wendell Miley (W)

Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.
ORCID: 0000-0001-8435-9982

Kyle Moore (K)

Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.

Romin Roshan (R)

Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.

Denise Whitby (D)

Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD.

Angela Shaulov Kask (AS)

Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.

Judith Kaiser (J)

Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
ORCID: 0000-0001-7165-7200

Emma Han (E)

Cytel (Shanghai) Co Ltd, Shanghai, China.

Anna Wright (A)

Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.

Robert Yarchoan (R)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
ORCID: 0000-0002-3057-1395

Steven P Fling (SP)

Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
ORCID: 0000-0001-6263-0153

Thomas S Uldrick (TS)

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
ORCID: 0000-0001-6959-0924

Classifications MeSH